» Articles » PMID: 37243119

Immunostaining of βA-Activin and Follistatin Is Decreased in HPV(+) Cervical Pre-Neoplastic and Neoplastic Lesions

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 May 27
PMID 37243119
Authors
Affiliations
Soon will be listed here.
Abstract

The activin-follistatin system regulates several cellular processes, including differentiation and tumorigenesis. We hypothesized that the immunostaining of βA-activin and follistatin varies in neoplastic cervical lesions. Cervical paraffin-embedded tissues from 162 patients sorted in control ( = 15), cervical intraepithelial neoplasia (CIN) grade 1 ( = 38), CIN2 ( = 37), CIN3 ( = 39), and squamous cell carcinoma (SCC; = 33) groups were examined for βA-activin and follistatin immunostaining. Human papillomavirus (HPV) detection and genotyping were performed by PCR and immunohistochemistry. Sixteen samples were inconclusive for HPV detection. In total, 93% of the specimens exhibited HPV positivity, which increased with patient age. The most detected high-risk (HR)-HPV type was HPV16 (41.2%) followed by HPV18 (16%). The immunostaining of cytoplasmatic βA-activin and follistatin was higher than nuclear immunostaining in all cervical epithelium layers of the CIN1, CIN2, CIN3, and SCC groups. A significant decrease ( < 0.05) in the cytoplasmic and nuclear immunostaining of βA-activin was detected in all cervical epithelial layers from the control to the CIN1, CIN2, CIN3, and SCC groups. Only nuclear follistatin immunostaining exhibited a significant reduction ( < 0.05) in specific epithelial layers of cervical tissues from CIN1, CIN2, CIN3, and SCC compared to the control. Decreased immunostaining of cervical βA-activin and follistatin at specific stages of CIN progression suggests that the activin-follistatin system participates in the loss of the differentiation control of pre-neoplastic and neoplastic cervical specimens predominantly positive for HPV.

Citing Articles

The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance.

Sosa J, Oyelakin A, Sinha S Biology (Basel). 2024; 13(2).

PMID: 38392348 PMC: 10887188. DOI: 10.3390/biology13020130.

References
1.
Herfs M, Yamamoto Y, Laury A, Wang X, Nucci M, McLaughlin-Drubin M . A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A. 2012; 109(26):10516-21. PMC: 3387104. DOI: 10.1073/pnas.1202684109. View

2.
Loomans H, Andl C . Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion. Cancers (Basel). 2015; 7(1):70-91. PMC: 4381251. DOI: 10.3390/cancers7010070. View

3.
Gheit T . Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology. Front Oncol. 2019; 9:355. PMC: 6517478. DOI: 10.3389/fonc.2019.00355. View

4.
Yamaguchi A, Hashimoto N, Tsutae W, Seino K, Ebina Y, Tokino T . Detection of human papillomavirus DNA by PCR/microfluorometry for screening of cervical cancer. Clin Chim Acta. 2002; 318(1-2):41-9. DOI: 10.1016/s0009-8981(01)00795-1. View

5.
Molijn A, Kleter B, Quint W, van Doorn L . Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol. 2005; 32 Suppl 1:S43-51. DOI: 10.1016/j.jcv.2004.12.004. View